ArticleFrontiers in pharmacology2023

Which is the top player for the cardiovascular safety? ibrutinib vs. obinutuzumab in CLL.

Annamaria Mascolo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.